Aposense, an Israeli publicly-traded biopharmaceutical company (TASE: APOS), is focused on a novel and powerful natural energy resource: the membrane dipole potential, a recently-discovered voltage, measurable in every leaflet of any phospholipid membrane. The dipole potential translates into an enormously strong electric field of up to 1 billion V/m (!), spanning ~30 Å, from membrane surface to membrane center. Excitingly, this electric potential, and its related internal membrane electric field (IMEF) have not been recruited to date for any medical application.
Fascinated by the fact that every cell harbors its own discrete and strong powerhouse, Aposense developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities, capable of "energy mining" from the IMEF, and its translation into kinetic energy, for movement within the hydrophobic membrane core.
Upon linkage to a cargo drug, this intra-mem¬brane movement of the MNMs can be utilized for energy-consuming tasks, such as enabling the delivery of siRNA into the cytoplasm, where they exert their pharmacological effects, e.g., gene silencing, or moving the drug into drug depot sites generated at the depths of the phospholipid membranes. In both scenarios, Aposense’s MNM are improving pivotal drug features.